One of the main issues with neurofilament and with the implementation of neurofilament in clinical practice is that we don’t have widely accepted cut-offs. There are some cut-offs that are based on age, others that are based on age and BMI, others that are age-specific, so we have different cut-offs for different age ranges. And this creates a sort of difficulty in clinical application. In our study, we first did measurements of neurofilament in people with MS, on plasma neurofilament actually, in people with MS...
One of the main issues with neurofilament and with the implementation of neurofilament in clinical practice is that we don’t have widely accepted cut-offs. There are some cut-offs that are based on age, others that are based on age and BMI, others that are age-specific, so we have different cut-offs for different age ranges. And this creates a sort of difficulty in clinical application. In our study, we first did measurements of neurofilament in people with MS, on plasma neurofilament actually, in people with MS. And then we computed the different cut-offs and categorized patients depending on the different cut-offs, adjusting by age or referring to the specific age range or using the BMI as well, etc. And the very result was that basically they were more or less the same. So I think so far we have been using a lot of energy trying to find different cut-offs, but it was very good to see that the different cut-offs were actually very similar. So I believe this is a huge step forward towards the application of neurofilament.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.